Relationship between tumor DNA methylation status and patient characteristics in african-american and european-american women with breast cancer

Songping Wang, Tiffany H. Dorsey, Atsushi Terunuma, Rick A Kittles, Stefan Ambs, Bernard Kwabi-Addo

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Aberrant DNA methylation is critical for development and progression of breast cancer. We investigated the association of CpG island methylation in candidate genes and clinicopathological features in 65 African-American (AA) and European-American (EA) breast cancer patients. Quantitative methylation analysis was carried out on bisulfite modified genomic DNA and sequencing (pyrosequencing) for promoter CpG islands of p16, ESR1, RASSF1A, RARβ2, CDH13, HIN1, SFRP1 genes and the LINE1 repetitive element using matched paired non-cancerous and breast tumor specimen (32 AA and 33 EA women). Five of the genes, all known tumor suppressor genes (RASSF1A, RARβ2, CDH13, HIN1 and SFRP1), were found to be frequently hypermethylated in breast tumor tissues but not in the adjacent non-cancerous tissues. Significant differences in the CDH13 methylation status were observed by comparing DNA methylation between AA and EA patients, with more obvious CDH13 methylation differences between the two patient groups in the ER- disease and among young patients (age<50). In addition, we observed associations between CDH13, SFRP1, and RASSF1A methylation and breast cancer subtypes and between SFRP1 methylation and patient's age. Furthermore, tumors that received neoadjuvant therapy tended to have reduced RASSF1A methylation when compared with chemotherapy naïve tumors. Finally, Kaplan Meier survival analysis showed a significant association between methylation at 3 loci (RASSF1A, RARβ2 and CDH13) and reduced overall disease survival. In conclusion, the DNA methylation status of breast tumors was found to be significantly associated with clinicopathological features and race/ethnicity of the patients.

Original languageEnglish (US)
Article numbere37928
JournalPLoS One
Volume7
Issue number5
DOIs
StatePublished - May 31 2012
Externally publishedYes

Fingerprint

Methylation
DNA methylation
DNA Methylation
African Americans
methylation
breast neoplasms
Tumors
Breast Neoplasms
neoplasms
Neoplasms
Genes
CpG Islands
Association reactions
Tissue
bisulfites
Neoadjuvant Therapy
tumor suppressor genes
Chemotherapy
genes
European Americans

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Relationship between tumor DNA methylation status and patient characteristics in african-american and european-american women with breast cancer. / Wang, Songping; Dorsey, Tiffany H.; Terunuma, Atsushi; Kittles, Rick A; Ambs, Stefan; Kwabi-Addo, Bernard.

In: PLoS One, Vol. 7, No. 5, e37928, 31.05.2012.

Research output: Contribution to journalArticle

Wang, Songping ; Dorsey, Tiffany H. ; Terunuma, Atsushi ; Kittles, Rick A ; Ambs, Stefan ; Kwabi-Addo, Bernard. / Relationship between tumor DNA methylation status and patient characteristics in african-american and european-american women with breast cancer. In: PLoS One. 2012 ; Vol. 7, No. 5.
@article{edc4a72b0548435b93cb597736fc8487,
title = "Relationship between tumor DNA methylation status and patient characteristics in african-american and european-american women with breast cancer",
abstract = "Aberrant DNA methylation is critical for development and progression of breast cancer. We investigated the association of CpG island methylation in candidate genes and clinicopathological features in 65 African-American (AA) and European-American (EA) breast cancer patients. Quantitative methylation analysis was carried out on bisulfite modified genomic DNA and sequencing (pyrosequencing) for promoter CpG islands of p16, ESR1, RASSF1A, RARβ2, CDH13, HIN1, SFRP1 genes and the LINE1 repetitive element using matched paired non-cancerous and breast tumor specimen (32 AA and 33 EA women). Five of the genes, all known tumor suppressor genes (RASSF1A, RARβ2, CDH13, HIN1 and SFRP1), were found to be frequently hypermethylated in breast tumor tissues but not in the adjacent non-cancerous tissues. Significant differences in the CDH13 methylation status were observed by comparing DNA methylation between AA and EA patients, with more obvious CDH13 methylation differences between the two patient groups in the ER- disease and among young patients (age<50). In addition, we observed associations between CDH13, SFRP1, and RASSF1A methylation and breast cancer subtypes and between SFRP1 methylation and patient's age. Furthermore, tumors that received neoadjuvant therapy tended to have reduced RASSF1A methylation when compared with chemotherapy na{\"i}ve tumors. Finally, Kaplan Meier survival analysis showed a significant association between methylation at 3 loci (RASSF1A, RARβ2 and CDH13) and reduced overall disease survival. In conclusion, the DNA methylation status of breast tumors was found to be significantly associated with clinicopathological features and race/ethnicity of the patients.",
author = "Songping Wang and Dorsey, {Tiffany H.} and Atsushi Terunuma and Kittles, {Rick A} and Stefan Ambs and Bernard Kwabi-Addo",
year = "2012",
month = "5",
day = "31",
doi = "10.1371/journal.pone.0037928",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Relationship between tumor DNA methylation status and patient characteristics in african-american and european-american women with breast cancer

AU - Wang, Songping

AU - Dorsey, Tiffany H.

AU - Terunuma, Atsushi

AU - Kittles, Rick A

AU - Ambs, Stefan

AU - Kwabi-Addo, Bernard

PY - 2012/5/31

Y1 - 2012/5/31

N2 - Aberrant DNA methylation is critical for development and progression of breast cancer. We investigated the association of CpG island methylation in candidate genes and clinicopathological features in 65 African-American (AA) and European-American (EA) breast cancer patients. Quantitative methylation analysis was carried out on bisulfite modified genomic DNA and sequencing (pyrosequencing) for promoter CpG islands of p16, ESR1, RASSF1A, RARβ2, CDH13, HIN1, SFRP1 genes and the LINE1 repetitive element using matched paired non-cancerous and breast tumor specimen (32 AA and 33 EA women). Five of the genes, all known tumor suppressor genes (RASSF1A, RARβ2, CDH13, HIN1 and SFRP1), were found to be frequently hypermethylated in breast tumor tissues but not in the adjacent non-cancerous tissues. Significant differences in the CDH13 methylation status were observed by comparing DNA methylation between AA and EA patients, with more obvious CDH13 methylation differences between the two patient groups in the ER- disease and among young patients (age<50). In addition, we observed associations between CDH13, SFRP1, and RASSF1A methylation and breast cancer subtypes and between SFRP1 methylation and patient's age. Furthermore, tumors that received neoadjuvant therapy tended to have reduced RASSF1A methylation when compared with chemotherapy naïve tumors. Finally, Kaplan Meier survival analysis showed a significant association between methylation at 3 loci (RASSF1A, RARβ2 and CDH13) and reduced overall disease survival. In conclusion, the DNA methylation status of breast tumors was found to be significantly associated with clinicopathological features and race/ethnicity of the patients.

AB - Aberrant DNA methylation is critical for development and progression of breast cancer. We investigated the association of CpG island methylation in candidate genes and clinicopathological features in 65 African-American (AA) and European-American (EA) breast cancer patients. Quantitative methylation analysis was carried out on bisulfite modified genomic DNA and sequencing (pyrosequencing) for promoter CpG islands of p16, ESR1, RASSF1A, RARβ2, CDH13, HIN1, SFRP1 genes and the LINE1 repetitive element using matched paired non-cancerous and breast tumor specimen (32 AA and 33 EA women). Five of the genes, all known tumor suppressor genes (RASSF1A, RARβ2, CDH13, HIN1 and SFRP1), were found to be frequently hypermethylated in breast tumor tissues but not in the adjacent non-cancerous tissues. Significant differences in the CDH13 methylation status were observed by comparing DNA methylation between AA and EA patients, with more obvious CDH13 methylation differences between the two patient groups in the ER- disease and among young patients (age<50). In addition, we observed associations between CDH13, SFRP1, and RASSF1A methylation and breast cancer subtypes and between SFRP1 methylation and patient's age. Furthermore, tumors that received neoadjuvant therapy tended to have reduced RASSF1A methylation when compared with chemotherapy naïve tumors. Finally, Kaplan Meier survival analysis showed a significant association between methylation at 3 loci (RASSF1A, RARβ2 and CDH13) and reduced overall disease survival. In conclusion, the DNA methylation status of breast tumors was found to be significantly associated with clinicopathological features and race/ethnicity of the patients.

UR - http://www.scopus.com/inward/record.url?scp=84861712337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861712337&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0037928

DO - 10.1371/journal.pone.0037928

M3 - Article

C2 - 22701537

AN - SCOPUS:84861712337

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e37928

ER -